Influence of age and gender on risperidone plasma concentrations

被引:70
作者
Aichhorn, W
Weiss, U
Marksteiner, J
Kemmler, G
Walch, T
Zernig, G
Stelzig-Schoeler, R
Stuppaeck, C
Geretsegger, C
机构
[1] Innsbruck Med Univ, Dept Psychiat, A-6020 Innsbruck, Austria
[2] PMU Salzburg, Dept Psychiat 1, Salzburg, Austria
关键词
risperidone; 9-hydroxyrisperidone; plasma concentration; elderly; gender; therapeutic drug monitoring;
D O I
10.1177/0269881105053306
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
There is limited information on gender- and age-specific effects on plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone. The present study investigated dose- and weight-adjusted plasma concentrations of risperidone and its metabolite in three age groups (<45 years, 45-60 years, over 60 years). Gender-specific differences were examined in the whole sample and for the premenopausal subgroup. One hundred and twenty-nine patients (18-93 years) were included in the study, 52 (40%) mate and 77 (60%) female. Concentrations of risperidone and 9-hydroxyrisperidone were measured at steady-state by high-performance liquid chromatography with electrochemical detection (HPLC-ED). When total plasma concentrations (risperidone plus 9-hydroxyrisperidone) were adjusted for daily maintenance dose (ng/mL/mg = C/D ratio), significant differences between all age groups were found. We found a mean increase of the C/D ratio by 34.8% per decade in patients older than 42 years. No significant sex-related differences in the average plasma concentrations were observed for the whole sample and for the premenopausal subgroup. This study shows clear evidence of higher risperidone total plasma concentrations for patients over 40 years of age. This linear increase (over 30% per decade) may then lead to an increased incidence of adverse effects in elderly patients.
引用
收藏
页码:395 / 401
页数:7
相关论文
共 38 条
  • [1] Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: Reappraisal of interindividual variability factors
    Balant-Gorgia, AE
    Gex-Fabry, M
    Genet, C
    Balant, LP
    [J]. THERAPEUTIC DRUG MONITORING, 1999, 21 (01) : 105 - 115
  • [2] A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia
    Brodaty, H
    Ames, D
    Snowdon, J
    Woodward, M
    Kirwan, J
    Clarnette, R
    Lee, E
    Lyons, B
    Grossman, F
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (02) : 134 - 143
  • [3] Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine
    Carrillo, JA
    Herráiz, AG
    Ramos, SI
    Gervasini, G
    Vizcaíno, S
    Benítez, J
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2003, 23 (02) : 119 - 127
  • [4] ANALYSIS OF OLANZAPINE IN HUMAN PLASMA UTILIZING REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION
    CATLOW, JT
    BARTON, RD
    CLEMENS, M
    GILLESPIE, TA
    GOODWIN, M
    SWANSON, SP
    [J]. JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1995, 668 (01): : 85 - 90
  • [5] Pharmacodynamic and pharmacokinetic considerations in geriatric psychopharmacology
    Catterson, ML
    Preskorn, SH
    Martin, RL
    [J]. PSYCHIATRIC CLINICS OF NORTH AMERICA, 1997, 20 (01) : 205 - &
  • [6] AGE-ASSOCIATED STEREOSELECTIVE ALTERATIONS IN HEXOBARBITAL METABOLISM
    CHANDLER, MHH
    SCOTT, SR
    BLOUIN, RA
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 43 (04) : 436 - 441
  • [7] CHOUINARD G, 1993, CAN J PSYCHIAT, V38, P89
  • [8] CLINICAL PHARMACOKINETIC CONSIDERATIONS IN THE ELDERLY - AN UPDATE
    DAWLING, S
    CROME, P
    [J]. CLINICAL PHARMACOKINETICS, 1989, 17 (04) : 236 - 263
  • [9] Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4
    Fang, J
    Bourin, M
    Baker, GB
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1999, 359 (02) : 147 - 151
  • [10] GENDER DIFFERENCES IN HUMAN PHARMACOKINETICS AND PHARMACODYNAMICS
    FLETCHER, CV
    ACOSTA, EP
    STRYKOWSKI, JM
    [J]. JOURNAL OF ADOLESCENT HEALTH, 1994, 15 (08) : 619 - 629